Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Kaplan Meier Method

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    184 result(s) found for: Kaplan Meier Method. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-004197-42 Sponsor Protocol Number: CUSP9v3 Start Date*: 2016-08-02
    Sponsor Name:University Hospital of Ulm
    Full Title: A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for ...
    Medical condition: Glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000782-21 Sponsor Protocol Number: VHIO19001 Start Date*: 2019-06-25
    Sponsor Name:Vall d' Hebron Institute of Oncology (VHIO)
    Full Title: Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC) – MONEO Study
    Medical condition: Resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003896-37 Sponsor Protocol Number: ODO-TE-B201 Start Date*: 2019-06-18
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer ...
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001994-25 Sponsor Protocol Number: TACTI-002(IMP321P015);KeynotePN798 Start Date*: 2019-02-12
    Sponsor Name:Immutep S.A.S.
    Full Title: TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurren...
    Medical condition: Previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or recurrent or metastatic squamous head and neck cancer (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003715-28 Sponsor Protocol Number: HALO-109-201 Start Date*: 2011-12-08
    Sponsor Name:Halozyme, Inc.
    Full Title: A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined with PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Compared to Gemcitabine...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003398-91 Sponsor Protocol Number: ABI-007-PANC-003 Start Date*: 2014-05-15
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
    Medical condition: Subjects With Surgically Resected Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) HU (Completed) ES (Ongoing) IT (Completed) PT (Completed) BE (Completed) FI (Completed) IE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004889-15 Sponsor Protocol Number: R092670PSY3011 Start Date*: 2012-04-23
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) BE (Completed) DE (Completed) PT (Completed) AT (Completed) SE (Completed) DK (Prematurely Ended) SK (Completed) FI (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-004742-42 Sponsor Protocol Number: IFCT-1802 Start Date*: 2019-08-29
    Sponsor Name:IFCT
    Full Title: A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 t...
    Medical condition: Patient with a non small cell lung cancer and a poor general status
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.1 100000004867 10057364 Reduced general condition LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006413-33 Sponsor Protocol Number: 3206K2-104-WW Start Date*: 2008-02-14
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
    Medical condition: Relapsed or refractory B-cell Non Hodgkin's Lymphoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000992-26 Sponsor Protocol Number: VAPOR002 Start Date*: 2016-06-29
    Sponsor Name:University Medical Center Groningen
    Full Title: Volatile Anesthetic Protection Of Renal transplants 2
    Medical condition: kidney transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DK (Completed) ES (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001676-29 Sponsor Protocol Number: MK3475_PROMO Start Date*: 2016-10-27
    Sponsor Name:Oslo University Hospital (OUS)
    Full Title: PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgery
    Medical condition: Osteosarcoma, not eligible for curative surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003416-23 Sponsor Protocol Number: CRAD001LDE43 Start Date*: 2012-03-12
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open label, single arm trial to evaluate patients with metastatic renal cell carcinoma treated with everolimus after failure of first line therapy with sunitinib or pazopanib
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10038409 Renal cell carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001410-33 Sponsor Protocol Number: UZB-VUB-11-01 Start Date*: 2016-03-10
    Sponsor Name:UZ BRUSSEL
    Full Title: Randomized phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment o...
    Medical condition: stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005240-28 Sponsor Protocol Number: PTCL-Dasa01 Start Date*: 2014-06-10
    Sponsor Name:AOU di Bologna, Policlinico S.Orsola-Malpighi
    Full Title: OPEN LABEL, PHASE IIA MULTICENTER STUDY OF DASATINIB IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL) RELAPSED/REFRACTORY OR NOT AMENABLE TO CONVENTIONAL THERAPY-PTCL-DASA01
    Medical condition: PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002230 Anaplastic large cell lymphoma T- and-cell types refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004747-39 Sponsor Protocol Number: MK3475_MPNST Start Date*: Information not available in EudraCT
    Sponsor Name:Oslo University Hospital
    Full Title: A phase II study of pembrolizumab in patients with malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery
    Medical condition: Malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000238-73 Sponsor Protocol Number: CA021-002 Start Date*: 2019-01-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab...
    Medical condition: Advanced Solid Tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000917-34 Sponsor Protocol Number: 20-214-29/CA045-022 Start Date*: Information not available in EudraCT
    Sponsor Name:Nektar Therapeutics
    Full Title: A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk...
    Medical condition: Resected Stage IIIA (lymph node metastasis > 1 mm)/B/C/D and IV melanoma with no evidence of disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) GR (Completed) PL (Completed) AT (Completed) PT (Prematurely Ended) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000206-10 Sponsor Protocol Number: HLX02-BC01 Start Date*: 2017-08-31
    Sponsor Name:Shanghai Henlius Biotech Inc.
    Full Title: Double-blind, Randomized, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of Trastuzumab Biosimilar HLX02 and EU-sourced Herceptin® in Pr...
    Medical condition: Previously Untreated Overexpressing metastasic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-008211-26 Sponsor Protocol Number: ISS-DPII Start Date*: 2009-05-25
    Sponsor Name:ISTITUTO SUPERIORE DI SANITA`
    Full Title: Peptide-based vaccine in combination or not with chemotherapy in melanoma patients: a phase II randomized clinical study.
    Medical condition: advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006713-16 Sponsor Protocol Number: CP12-0604 Start Date*: 2008-09-02
    Sponsor Name:ImClone Systems Incorporated
    Full Title: Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant Melanoma
    Medical condition: Metastatic Malignant Melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA